brexucabtagene autoleucel

CHEBI:CHEBI_750987

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2572005
generic_name
brexucabtagene autoleucel
listing_expiration_date
20251231
dosage_form
SUSPENSION
route
INTRAVENOUS
marketing_start_date
20211001
package_marketing_start_date
20211001
marketing_category
BLA
product_type
CELLULAR THERAPY
brand_name
TECARTUS
brand_name_base
TECARTUS
product_ndc
71287-220
application_number
BLA125703
labeler_name
Kite Pharma, Inc.
manufacturer_name
Kite Pharma, Inc.
spl_id
766473ab-2795-4c9f-bbb3-1c25129626b9
active_ingredient_name
BREXUCABTAGENE AUTOLEUCEL
active_ingredient_strength
1000000 1/68mL
package_ndc
71287-220-02
package_description
1 BAG in 1 PACKAGE (71287-220-02) / 68 mL in 1 BAG (71287-220-01)
unii
4MD2J2T8SJ
spl_set_id
a16108c2-7ca7-45af-965e-54bda4713022
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class